US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
20 July 2011
Donna Young
Please Login to read the full article.
20 July 2011
Donna Young
Please Login to read the full article.
RELATED CONTENT
NEWS
- US FDA extends action date for BMS/AZ's diabetes drug as it assesses new data
- FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors
- US FDA rejects AZ/BMS diabetes drug dapagliflozin
- BMS and AZ to look at cardiprotective effect if dapagliflozin approved in diabetes
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
